Label: ATROPINE SULFATE- atropine sulfate solution
- NDC Code(s): 24208-750-06, 24208-750-60
- Packager: Bausch & Lomb Incorporated
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: unapproved drug other
If you are a consumer or patient please visit this version.
Atropine Sulfate Ophthalmic Solution USP, 1% is a sterile topical anticholinergic for ophthalmic use. The active ingredient is represented by the chemical structural formula:
Mol. wt. 694.84
Benzeneacetic acid, α-(hydroxymethyl)-, 8-methyl-8-azabicyclo-(3.2.1)oct-3-yl ester, endo-(±)-, sulfate (2:1) (salt), monohydrate.
Each mL Contains:
Atropine Sulfate Ophthalmic Solution USP, 1%, contains in each mL of solution: ACTIVE: Atropine Sulfate USP, 1% (10mg); INACTIVES: Boric Acid, Hypromellose and Purified Water; Sodium Hydroxide and/or Hydrochloric Acid may be added to adjust pH. PRESERVATIVE ADDED: Benzalkonium Chloride 0.01%.Close
- CHEMICAL PHARMACOLOGY
The anticholinergic effect of this product blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia).Close
- INDICATIONS AND USAGE
For mydriasis and/or cycloplegia. For cycloplegic refraction, for pupillary dilation desired in inflammatory conditions of the iris and uveal tract.Close
This product should not be used in patients with primary glaucoma or a predisposition to narrow anterior chamber angle glaucoma. This product should not be used in pediatric patients who have previously had a severe systemic reaction to atropine. This product should not be used in those persons showing hypersensitivity to any component of this preparation.Close
Not for injection into the eye. Do not touch dropper tip to any surface, as this may contaminate the solution. In pediatric patients, use with extreme caution. Excessive use in pediatric patients or in certain individuals with a previous history of susceptibility to belladonna alkaloids may produce systemic symptoms of atropine poisoning. If this occurs, discontinue medication, and use appropriate therapy as outlined in “OVERDOSAGE” section.Close
To avoid excessive systemic absorption, the lacrimal sac should be compressed by digital pressure for two to three minutes after instillation. To avoid inducing angle closure glaucoma, an estimation of the depth of the angle of the anterior chamber should be made. Administration of atropine in infants requires great caution.
Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated. Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation.
Parents should be warned not to get this preparation in their children’s mouth and to wash their own hands and the child’s hands following administration.
Carcinogenesis, Mutagenesis, Impairment of Fertility:
No studies have been conducted in animals or in humans to evaluate the potential of these effects.
Pregnancy Category C:
Animal reproduction studies have not been performed with atropine. It is also not known whether atropine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Atropine should be given to pregnant women only if clearly needed.
- ADVERSE REACTIONS
Prolonged use may produce local irritation characterized by follicular conjunctivitis, vascular congestion, edema, exudate, and an eczematoid dermatitis. Severe reactions are manifested by hypotension with progressive respiratory depression. Coma and death have been reported in the very young.Close
Systemic atropine toxicity is manifested by flushing and dryness of the skin (a rash may be present in pediatric patients), blurred vision, a rapid and irregular pulse, fever, abdominal distension in infants, mental aberration (hallucinosis) and loss of neuromuscular coordination.
Atropine poisoning, although distressing, is rarely fatal, even with large doses of atropine, and is self-limited if the cause is recognized and the atropine medication is discontinued. In severe intoxication, physostigmine salicylate may be administered parenterally to provide more prompt relief of the intoxication. Give physostigmine salicylate as 1-5 mL IV of dilution containing 1 mg in 5 mL of saline. The smaller dose is for pediatric patients, and injection should take not less than two minutes. EKG control is advisable. Dosage can be repeated every five minutes up to a total dose of 2 mg in pediatric patients and 6 mg in adults every 30 minutes. Physostigmine is contraindicated in hypotensive reactions. Atropine (1 mg) should be available for immediate injection if physostigmine causes bradycardia, convulsions or bronchoconstriction. In pediatric patients, the body surface must be kept moist.
Use extreme caution when employing short-acting barbiturates to control excitement.
- DOSAGE AND ADMINISTRATION
ATROPINE SULFATE SOLUTION: 1 or 2 drops in the eye(s) three times a day or as directed by a physician.
FOR OPHTHALMIC USE ONLY.
- HOW SUPPLIED
Atropine Sulfate Ophthalmic Solution USP, 1% is supplied in a plastic squeeze bottle with a controlled tip applicator in the following sizes:
5 mL bottle – NDC 24208-750-60
15 mL bottle – NDC 24208-750-06
DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT
Store between 15°-25°C (59°-77°F).
KEEP OUT OF REACH OF CHILDREN.
Revised: January 2013
Bausch & Lomb Incorporated
Tampa, FL 33637
©Bausch & Lomb Incorporated
- PACKAGE/LABEL PRINCIPAL DISPLAY PANEL
BAUSCH + LOMB
Atropine Sulfate Ophthalmic Solution USP, 1% (Sterile)
- INGREDIENTS AND APPEARANCE
atropine sulfate solution
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:24208-750 Route of Administration OPHTHALMIC DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength ATROPINE SULFATE (UNII: 03J5ZE7KA5) (ATROPINE - UNII:7C0697DR9I) ATROPINE SULFATE 10 mg in 1 mL Inactive Ingredients Ingredient Name Strength BORIC ACID (UNII: R57ZHV85D4) HYPROMELLOSES (UNII: 3NXW29V3WO) WATER (UNII: 059QF0KO0R) SODIUM HYDROXIDE (UNII: 55X04QC32I) HYDROCHLORIC ACID (UNII: QTT17582CB) BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:24208-750-60 1 in 1 CARTON 1 5 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product 2 NDC:24208-750-06 1 in 1 CARTON 2 15 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date Unapproved drug other 09/30/1990 09/30/2016 Labeler - Bausch & Lomb Incorporated (196603781) Establishment Name Address ID/FEI Business Operations Bausch & Lomb Incorporated 807927397 MANUFACTURE(24208-750)